Hepatitis B.
High frequency of functional anti-YMDD and -mutant cytotoxic
T lymphocytes after in vitro expansion correlates with successful response
to lamivudine therapy for chronic hepatitis B. Lin CL, Tsai SL, Lee TH,
et al. Gut 2005;54:152-61.
Inmunidad celular contra mutantes YMDD y eficacia
del tratamiento con lamivudina en pacientes con hepatitis crónica
B.
HBV genotypes and outcome of HBV infection. Jia-Horng Kao, Ding-Shinn Chen.
Hepatology 2005;41:216.
Carta.
Adefovir dipivoxil for chemotherapy-induced activation of
hepatitis B virusinfection. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia
MC. New England Journal of Medicine 2005;352:310-1.
Carta..
The potential of RNA interference as a tool in the management
of viral hepatitis. Taylor JA, Naoumov NV. Journal of Hepatology 2005;42:139-44.
Revisión.
Pegylated interferon alfa-2b alone or in combination with
lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Janssen
HL, van Zonneveld M, Senturk H, et al. Lancet 2005;365:123-9.
Eficacia del interferon pegilado en monoterapia
para el tratamiento de la infección crónica por el VHB.
